All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 19, 2022
Home » Blogs » BioWorld MedTech Perspectives » Rethinking Innovation

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Rethinking Innovation

Nov. 5, 2012
By Omar Ford
No Comments
CC_symbol_only[1]

If I had to sum up the key take away from Cleveland Clinic's Medical Innovation Summit last week, I would probably say something like this : Innovation is alive and well, but are hospitals and physicians willing to pay for it when capital is so strained?

Nearly every panel that I attended seemed to have that as an underlying theme. Everyone from Cleveland Clinic's own Dr. Joseph Iannotti to Medtronic's CEO Omar Ishrak made statements about innovation in healthcare and the importance of having it present in an environment where capital is limited and dollars are few.

Iannotti made the most recent comment about innovation on the closing day of the summit when he said, "High Cost technology is needed - we need to be more efficient in how we use it."

The Medical Innovation Summit was perhaps in a state of flux this year and not because of Hurricane Sandy and its impact into the proceedings (Kudos for Chris Coburn, the executive director of CCF Innovations – the technology arm of the Cleveland Clinic, his team for shuffling around the speakers and keeping the panel going despite the storm impeding traveling plans for many of the panelists).

But rather, the flux came from the lateral shift to med-tech firms and clinicians proving outcomes in therapy coming into fruition. The result is a shift in the way med-tech firms and clinicians are thinking about innovation.

One thing that was made apparent, was that the additional bells and whistles method that was perhaps touted in years past is fading out. Clinicians want simple tools that can get a job done better than some of the complex offerings out on the market.

Perhaps the greatest sign of this was in the Top 10 Innovations of 2013. From insurance plans to bariatric procedures, innovation is slated to occur much differently than in the past.

Below is the Number 1 Innovation of 2013.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 19, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 19, 2022.
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
  • TPOXX

    Siga leads monkeypox antiviral research, amid lack of interest from big pharma

    BioWorld
    After declarations from the World Health Organization and the U.S. government that monkeypox is a public health emergency, attention is turning to the pharma...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing